Chairperson
_____________
The committee on Mental Health, Substance Abuse Prevention, Children and Families reported and recommended:
Relating to excluding [18 F]FP-CIT.
hist199591Referred to the joint committee for review of Administrative Rules, February 25, 2025. Relating to scheduling Mesocarb.
hist199593Referred to the joint committee for review of Administrative Rules, February 25, 2025. Relating to national provider identifier requirement.
hist199595Referred to the joint committee for review of Administrative Rules, February 25, 2025. Relating to scheduling Methiopropamine.
hist199597Referred to the joint committee for review of Administrative Rules, February 25, 2025. Relating to excluding Fenfluramine.
hist199599Referred to the joint committee for review of Administrative Rules, February 25, 2025. Relating to monitored prescription drug history reports.
hist199601Referred to the joint committee for review of Administrative Rules, February 25, 2025. Relating to transferring Flualprazolam and scheduling four (4) synthetic benzodiazepine substances.
hist199603Referred to the joint committee for review of Administrative Rules, February 25, 2025. Relating to scheduling Zuranolone.
hist199605Referred to the joint committee for review of Administrative Rules, February 25, 2025. Relating to scheduling nine fentanyl-related substances.
hist199607Referred to the joint committee for review of Administrative Rules, February 25, 2025. Relating to mail delivered prescriptions.
hist199610Referred to the joint committee for review of Administrative Rules, February 25, 2025. JESSE JAMES
Chairperson